Physician profile
Khusroo Qureshi
NPI 1356380711
$4,116.89
in general payments reported to CMS, 2019-2025
18 companies · $3,279 in 2025
The $3,279 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $76.95 · 2022: $203 · 2023: $325 · 2024: $233 · 2025: $3,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,560 · Food and Beverage: $1,018 · Travel and Lodging: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,560.00 |
| Food and Beverage | $1,017.93 |
| Travel and Lodging | $259.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $2,913.48 | 2025 | Imetelstat |
| Novartis Pharmaceuticals Corporation | $340.79 | 2022-2024 | |
| Janssen Biotech, INC. | $179.21 | 2023-2025 | Rybrevant, Darzalex, Tecvayli |
| Pharmacyclics LLC, An Abbvie Company | $146.65 | 2020-2023 | Imbruvica, Epkinly |
| Merck Sharp & Dohme LLC | $126.70 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $85.34 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $71.63 | 2022-2025 | Opdivo |
| Pfizer INC. | $35.82 | 2022-2025 | |
| Intuitive Surgical, INC. | $32.07 | 2025 | |
| Aveo Pharmaceuticals, INC. | $28.65 | 2023 | Fotivda |
| Acrotech Biopharma INC. | $23.94 | 2022 | |
| Incyte Corporation | $23.33 | 2025 | Jakafi |
| Amgen INC. | $22.57 | 2023 | Nplate, Xgeva |
| Ge Healthcare | $20.97 | 2022 | |
| Tempus Ai, INC | $19.14 | 2025 | Xt Cdx |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $16.50 | 2024 | |
| Exelixis INC. | $15.70 | 2022 | |
| Daiichi Sankyo INC. | $14.40 | 2025 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khusroo Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.